BR112015019524A2 - tratamento de combinação - Google Patents

tratamento de combinação

Info

Publication number
BR112015019524A2
BR112015019524A2 BR112015019524A BR112015019524A BR112015019524A2 BR 112015019524 A2 BR112015019524 A2 BR 112015019524A2 BR 112015019524 A BR112015019524 A BR 112015019524A BR 112015019524 A BR112015019524 A BR 112015019524A BR 112015019524 A2 BR112015019524 A2 BR 112015019524A2
Authority
BR
Brazil
Prior art keywords
taxane
pharmaceutically acceptable
acceptable salt
compound
treatment
Prior art date
Application number
BR112015019524A
Other languages
English (en)
Other versions
BR112015019524A8 (pt
Inventor
Robert Davies Barry
Chiara Cosulich Sabrina
Joy Hancox Ursula
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112015019524A2 publication Critical patent/BR112015019524A2/pt
Publication of BR112015019524A8 publication Critical patent/BR112015019524A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

resumo patente de invenção: "tratamento de combinação". a presente invenção refere-se ao uso de combinações que compreendem 8-[(1r)-1-(3,5-difluorofenilamino)etil]-n,n-dimetil-2-morfolino-4-oxo-4h-cromeno-6-carboxamida ou um sal farmaceuticamente aceitável do mesmo e um taxano no tratamento ou profilaxia de câncer, composições farmacêuticas que compreendem o composto [i] (ou um sal farmaceuticamente aceitável do mesmo) e um taxano; kits que compreendem o composto [i] ou um sal farmaceuticamente aceitável do mesmo e um taxano, opcionalmente com instruções para uso; e métodos de tratamento que compreendem a administração simultânea, sequencial ou separada de composto [i] ou um sal farmaceuticamente aceitável do mesmo e um taxano ao animal de sangue quente, tal como um homem.
BR112015019524A 2013-03-04 2014-03-03 combinação de um composto [i] com um taxano, método de produção de efeito anticancer, uso de um composto [i] em combinação com um taxano, composição farmacêutica e kit no tratamento de câncer BR112015019524A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772079P 2013-03-04 2013-03-04
US201361771974P 2013-03-04 2013-03-04
PCT/GB2014/050618 WO2014135851A1 (en) 2013-03-04 2014-03-03 Combination treatment

Publications (2)

Publication Number Publication Date
BR112015019524A2 true BR112015019524A2 (pt) 2017-07-18
BR112015019524A8 BR112015019524A8 (pt) 2019-11-19

Family

ID=50288179

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019524A BR112015019524A8 (pt) 2013-03-04 2014-03-03 combinação de um composto [i] com um taxano, método de produção de efeito anticancer, uso de um composto [i] em combinação com um taxano, composição farmacêutica e kit no tratamento de câncer

Country Status (13)

Country Link
US (1) US9763950B2 (pt)
EP (1) EP2964217B1 (pt)
JP (1) JP6546098B2 (pt)
KR (1) KR102222346B1 (pt)
CN (1) CN105142629B (pt)
AU (1) AU2014224445C1 (pt)
BR (1) BR112015019524A8 (pt)
CA (1) CA2900136C (pt)
ES (1) ES2754034T3 (pt)
HK (1) HK1216391A1 (pt)
MX (1) MX362905B (pt)
RU (1) RU2666999C2 (pt)
WO (1) WO2014135851A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3765035A4 (en) * 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND ETERNAL CANCER USING TAXANNANO PARTICLES

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634994B2 (en) 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CN100462066C (zh) 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
RU2284818C2 (ru) * 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US7598377B2 (en) 2002-08-16 2009-10-06 Astrazeneca Ab Inhibition of phosphoinositide 3-kinase β
DE602004024115D1 (de) 2003-12-09 2009-12-24 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
HUE048521T2 (hu) 2005-08-31 2020-08-28 Abraxis Bioscience Llc Gyengén vízoldékony gyógyszerészeti és antimikrobális hatóanyagokat tartalmazó keverékek
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
BR112013025410A2 (pt) 2011-04-01 2016-12-20 Astrazeneca Ab tratamento terapêutico

Also Published As

Publication number Publication date
MX2015011588A (es) 2015-12-09
AU2014224445C1 (en) 2017-07-27
JP6546098B2 (ja) 2019-07-17
CN105142629A (zh) 2015-12-09
EP2964217B1 (en) 2019-08-28
ES2754034T3 (es) 2020-04-15
BR112015019524A8 (pt) 2019-11-19
KR102222346B1 (ko) 2021-03-02
AU2014224445A1 (en) 2015-08-27
US9763950B2 (en) 2017-09-19
CA2900136A1 (en) 2014-09-12
HK1216391A1 (zh) 2016-11-11
JP2016510060A (ja) 2016-04-04
CN105142629B (zh) 2018-11-23
AU2014224445B2 (en) 2017-02-02
EP2964217A1 (en) 2016-01-13
MX362905B (es) 2019-02-25
WO2014135851A1 (en) 2014-09-12
RU2666999C2 (ru) 2018-09-13
US20160022690A1 (en) 2016-01-28
CA2900136C (en) 2021-05-04
KR20150122145A (ko) 2015-10-30
RU2015139515A (ru) 2017-04-10

Similar Documents

Publication Publication Date Title
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
UY35907A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112014026703A2 (pt) inibidores de dna-pk
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
PH12016502352A1 (en) Pharmaceutical composition
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
BR112016002311A2 (pt) combinações de inibidor de cinase de pim
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112015019524A2 (pt) tratamento de combinação
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time